FDA Approvals of 2012

28 of 39


Drug: Fycompa
Generic molecule: perampanel
Company: Eisai
Approval date: Oct. 22

The scoop: Eisai's Fycompa is a glutamate receptor antagonist and the first of its kind designed to treat epilepsy. The drug is a blockbuster hopeful for the Japanese drugmaker, and analysts have projected it could bring in $500 million in sales by 2015 and eventually break the $1 billion barrier.